CD23 ANTIGEN DENSITY IS RELATED TO SERUM GAMMA-GLOBULIN LEVEL, BONE-MARROW RETICULIN PATTERN, AND TREATMENT IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA

被引：17

作者：

LAVABREBERTRAND, T

EXBRAYAT, C

BOURQUARD, P

LAVABREBERTRAND, C

FEGUEUX, N

PONCELET, P

ROUSSET, T

TAIB, J

EMBERGER, JM

NAVARRO, M

机构：

[1] Service des Maladies du Sang, Hôpital Lapeyronie, Montpellier

[2] INSERM U291, Montpellier

[3] Laboratoire d'Hématologie, Hôpital Saint Eloi, Montpellier

[4] Laboratoire d'Hématologie, Faculté de MCdecine, Marseille

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 13卷 / 1-2期

关键词：

CD23; CHRONIC LYMPHOCYTIC LEUKEMIA; HYPOGAMMAGLOBULINEMIA; BONE MARROW FIBROSIS;

D O I：

10.3109/10428199409051656

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The CD23 antigen density was evaluated by a cytofluorometric technique in 55 patients with chronic lymphocytic leukemia. The quantification method was based on the use of biological standards in indirect immunofluorescence. The CD23 antigen density was correlated with the percentage of CD23 positive cells, but antigen density appeared to be a more informative parameter. CD23 antigen density was lower in stage B than in stages A or C patients, and higher in patients undergoing chemotherapy or previously treated than in untreated patients. There was a significant negative correlation between CD23 antigen density and serum gamma globulin and IgG levels, that existed only in patients in an advanced stage of the disease. CD23 antigen density was higher in patients with abnormal bone marrow reticulin pattern. Serum gamma globulin level was lower in these patients, as well as in patients with prognostically unfavorable histologic bone marrow infiltration pattern. These data emphasize the interest of antigen density as an additional parameter and the complex relationship between CD23 expression, hypogammaglobulinemia, bone marrow histologic findings, and treatment in chronic lymphocytic leukemia.

引用

页码：89 / 94

页数：6

共 25 条

[1]

Foon K.A., Todd R.F., Immunologic classification of leukemia and lymphoma, Blood, 68, pp. 1-31, (1986)

[2]

Freedman A.S., Nadler L.M., B cell develop ment in chronic lymphocytic leukemia, Semin. Hematol., 24, pp. 230-239, (1987)

[3]

Freedman A.S., Nadler L.M., The relationship of chronic lymphocytic leukemia to normal activated B cells, Leukemia and Lymphoma, 1, pp. 293-300, (1990)

[4]

Legac E., Chastang C., Binet J.L., Michel A., Debre P., Merle-Beral H., Proposals for a phenotypic classification of B-chronic lymphocytic leukemia, relationship with prognostic factors, Leukemia and Lymphoma, 5, pp. 53-58, (1991)

[5]

Sarfati M., Fournier S., Christoffersen M., Biron G., Expression of CD23 antigen and its regulation by IL-4 in chronic lymphocytic leukemia, Leuk. Res., 14, pp. 47-55, (1990)

[6]

Merle-Beral H., Blanc C., Chastang C., Debre P., Phenotypic heterogeneity of B and T cell differentiation antigens in B CLL, Eur. J. Haematol., 41, pp. 197-203, (1988)

[7]

Geisler C.H., Larsen J.K., Hansen N.E., Hansen M.M., Christensen B.E., Lund B., Nielsen H., Plesner T., Thorling K., Andersen E., Andersen P.K., Prog nostic importance of flow cytometry phenotyping of 540 con secutive patients with B-cell chronic lymphocytic leukemia, Blood, 78, pp. 1795-1802, (1991)

[8]

Dadmarz R., Cawley J.C., Heterogeneity of CLL high CD23 antigen and aIFN receptor expression are features of favourable disease and of cell activation, Br. J. Haematol., 68, pp. 279-282, (1988)

[9]

Kimby E., Mellstedt H., Bjorkholm M., Holm G., Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of unknown significance, Eur. J. Haematol., 43, pp. 452-459, (1989)

[10]

Gibson J., Neville S., Joshua D., Kroninberg H., CD23 antigen expression in CLL, Br. J. Haematol., 72, (1989)

← 1 2 3 →